Results 161 to 170 of about 300,160 (284)

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

BMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou, Jia Liu, Shulin Lai, Suhan Yin, Bingmin Luo, Longquan Shao, Yiyuan Kang   +6 more
wiley   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

BMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao, Rui Qu, Zan Dai, Xiqun Jiang, Xu Zhen   +4 more
wiley   +1 more source

A Prospective, Multicenter, Open Label Study Investigating the Implementation of a Standardized Algorithm for Coronary CaLcificatiOn With PlaquE Modification Using UltraSound Guidance to Improve Procedural and Clinical Outcomes (CYCLOPES): Design and Rationale of the CYCLOPES Trial

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Introduction Moderate‐to‐severe calcification is present in ~20%–30% of patients undergoing coronary angiography. Coronary lesion modification is often necessary to facilitate optimal stent delivery and expansion, with several dedicated devices now approved for calcium modification before stent implantation. The CYCLOPES study aims to evaluate
Daniel O'Callaghan, Rory Durand, Colm G. Hanratty, Thomas Cuisset, Beatriz Vaquerizo, Jan‐Malte Sinning, Peter O'Kane, J. J. Coughlan, Simon Walsh, Róisín Colleran, Himanshu Rai, Osama Soliman, Emanuele Barbato, Barbara E. Stähli, Robert A. Byrne   +14 more
wiley   +1 more source

TLR agonists as adjuvants for viral vaccines: mechanisms, applications, and future directions. [PDF]

Front Microbiol
Shao F, Zhu X, Yi M, Gao H, Wu J, Fang R, Xie Y, Han J, Lu H.   +8 more
europepmc   +1 more source

Burden of Liver Disease Among Individuals With Turner Syndrome and Klinefelter Syndrome: A Comprehensive Perspective

Chronic Diseases and Translational Medicine, EarlyView.
ABSTRACT The liver is increasingly recognized as a major regulator of systemic cardio‐renal‐metabolic health. Evidence is mounting that sex‐chromosome dosage per se itself, independent of gonadal sex hormones, modulates hepatic physiology and liver disease risk.
Mohamad Jamalinia, Amedeo Lonardo, Ralf Weiskirchen   +2 more
wiley   +1 more source

Current update on toll-like receptors and prostate cancer: a decade of progress and emerging insights. [PDF]

Front Immunol
Janjirala J, Blanton M, Ramos KS, Zhang D.   +3 more
europepmc   +1 more source

Synthetic Cathepsin B Sensitive Adjuvant‐Peptide Conjugates to Target Intracellular Toll‐Like Receptors 7 and 8

ChemistryEurope, EarlyView.
Cathepsin B‐sensitive peptide–adjuvant conjugates are designed, synthesized, and evaluated to deliver an antigenic peptid and an adjuvant targeting Toll‐like receptors 7 and 8 (TLR7/8) to antigen presenting cells. The adjuvant is released by cathepsin B resulting in antigen presentation and TLR mediated T cell activation.
Marjolein M. E. Isendoorn, Giulia Castello, Nico J. Meeuwenoord, Martijn Verdoes, Jeroen D. C. Codée, Ferry Ossendorp, Dmitri V. Filippov   +6 more
wiley   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Toll like receptor agonist effects on human CD8+ T cell activation and expression of T cell checkpoint receptors. [PDF]

Hum Vaccin Immunother
Jeon D, Moseman JE, Hill E, McNeel DG.
europepmc   +1 more source

Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.
Abstract The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...
Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia   +4 more
wiley   +1 more source